{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:32:45Z","timestamp":1787841165717,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To compare the efficacy and safety of Stivant\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (biosimilar bevacizumab, CinnaGen, Iran) to Avastin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (innovator bevacizumab, Genentech, South San Francisco, CA) in premature infants with prethreshold type I retinopathy of prematurity (ROP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Preterm infants with bilateral prethreshold type 1 ROP were enrolled in this nonrandomized contralateral clinical trial. Bilateral intravitreal bevacizumab (IVB) was administered, with Stivant\n                      <jats:sup>\u00ae<\/jats:sup>\n                      injected in one eye and Avastin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in the other. Patients were followed up weekly for 4 weeks, then biweekly until complete retinal vascularization. Efficacy was evaluated based on disease activity regression (plus disease regression) and complete retinal vascularization. Safety was assessed through the monitoring of adverse events such as uveitis and endophthalmitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-four infants were included in the study. The mean age at IVB injection was 34.5 weeks. Complete retinal vascularization occurred at a mean age of 60.02 weeks for Stivant\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and 59.93 weeks for Avastin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.59). Five patients (11.3%) underwent bilateral laser photocoagulation as rescue treatment. Our results showed that Stivant\n                      <jats:sup>\u00ae<\/jats:sup>\n                      was noninferior to Avastin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in retinal vascularization progress. However, this study cannot make definitive noninferiority claims due to the sample size and its design as a pilot investigation. No cases of endophthalmitis or uveitis were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Stivant\n                      <jats:sup>\u00ae<\/jats:sup>\n                      exhibited noninferiority to Avastin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in efficacy and demonstrated a comparable safety profile in treating prethreshold type I ROP. A definite conclusion requires more extended studies with a larger sample size.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_178_24","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:02:39Z","timestamp":1758232959000},"page":"407-412","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Biosimilar Bevacizumab (Stivant\u00ae) versus Reference Product (Avastin\u00ae) in Prethreshold Type I Retinopathy of Prematurity"],"prefix":"10.4103","volume":"36","author":[{"given":"Mojtaba","family":"Abrishami","sequence":"first","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Ocular Oncology Service, Department of Ophthalmology and Visual Sciences, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Golmohammadi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Shoeibi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Ansari-Astaneh","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Sakhayi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Abrishami","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Maryam","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Bakhtiari","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Motamed Shariati","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12886-018-0732-3","article-title":"Prevalence and risk factors of retinopathy of prematurity in Iran: A systematic review and meta-analysis","volume":"18","author":"Azami","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/ICU.0000000000000783","article-title":"Complications of retinopathy of prematurity treatment","volume":"32","author":"Barnett","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.ophtha.2016.04.035","article-title":"Diagnostic discrepancies in retinopathy of prematurity classification","volume":"123","author":"Campbell","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20250918","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0161-6420(01)00540-1","article-title":"The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP)","volume":"108","author":"Good","year":"2001","journal-title":"Ophthalmology"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2015.12.005","article-title":"Practice patterns in retinopathy of prematurity treatment for disease milder than recommended by guidelines","volume":"163","author":"Gupta","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm11010039","article-title":"Treatment outside the recommended guidelines for retinopathy of prematurity (ROP): Prevalence, characteristics, and issues","volume":"11","author":"Lema\u00eetre","year":"2021","journal-title":"J Clin Med"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-022-00364-6","article-title":"Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity","volume":"8","author":"Mirghorbani","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"R9-20250918","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R10-20250918","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41433-019-0643-4","article-title":"Retinopathy of prematurity treatment: Asian perspectives","volume":"34","author":"Sen","year":"2020","journal-title":"Eye (Lond)"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.4103\/ijo.IJO_1827_19","article-title":"Operational guidelines for ROP in India: A summary","volume":"68","author":"Shukla","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","article-title":"Current and future trends in treatment of severe retinopathy of prematurity","volume":"40","author":"Wallace","year":"2013","journal-title":"Clin Perinatol"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","article-title":"An introduction to biosimilars for the treatment of retinal diseases: A narrative review","volume":"11","author":"Hariprasad","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R15-20250918","doi-asserted-by":"crossref","first-page":"28","DOI":"10.18502\/jovr.v16i1.8248","article-title":"Intraocular injection of Stivant\u00ae (a biosimilar to bevacizumab): A case series","volume":"16","author":"Mirshahi","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"key":"R16-20250918","first-page":"18104","article-title":"Retinopathy of prematurity: Treatment-needed patients, treatment complications, and recurrence rate","volume":"11","author":"Ansari-Astaneh","year":"2023","journal-title":"Int J Pediatr"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.11.002","article-title":"Strengths, weaknesses and future challenges of biosimilars\u2019 development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice","volume":"126","author":"Scavone","year":"2017","journal-title":"Pharmacol Res"},{"key":"R22-20250918","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bjophthalmol-2019-314443","article-title":"Understanding biosimilars and its regulatory aspects across the globe: An ophthalmology perspective","volume":"104","author":"Sharma","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R23-20250918","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/OPTH.S180393","article-title":"Biosimilars in ophthalmology: Is there a big change on the horizon?","volume":"12","author":"Sharma","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"273","DOI":"10.18502\/jovr.v15i3.7444","article-title":"The development pathway for biosimilar biotherapeutics","volume":"15","author":"Zarbin","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"key":"R25-20250918","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/kjo.kjo_18_17","article-title":"Safety and efficacy of Razumab-the new biosimilar in India: Our experience","volume":"28","author":"Sameera","year":"2016","journal-title":"Kerala J Ophthalmol"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of razumab\u00ae (the world\u2019s first biosimilar of ranibizumab) in retinal vein occlusion: A subgroup analysis of the pooled retrospective RE-ENACT study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmologica"},{"key":"R27-20250918","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4103\/ijo.IJO_973_22","article-title":"Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity","volume":"71","author":"Prajapati","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R28-20250918","doi-asserted-by":"crossref","first-page":"406","DOI":"10.21474\/IJAR01\/6234","article-title":"Retrospective efficacy and safety analysis of zybev (biosimilar of bevacizumab) use at tertiary eye care centres in India: Spectra trial","volume":"6","author":"Warudkar","year":"2018","journal-title":"Int J Adv Res"},{"key":"R29-20250918","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.clinthera.2020.03.009","article-title":"Efficacy and safety of proposed bevacizumab biosimilar BE1040V in patients with metastatic colorectal cancer: A phase III, randomized, double-blind, noninferiority clinical trial","volume":"42","author":"Rezvani","year":"2020","journal-title":"Clin Ther"},{"key":"R30-20250918","doi-asserted-by":"crossref","first-page":"341","DOI":"10.18502\/jovr.v15i3.7453","article-title":"Safety of intravitreal injection of stivant, a biosimilar to bevacizumab, in rabbit eyes","volume":"15","author":"Lashay","year":"2020","journal-title":"J Ophthalmic Vis Res"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_178_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:44:22Z","timestamp":1787838262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_178_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_178_24","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}